KLF1, Peptide

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 19; NC_000019.9 (12995236..12998017, complement). Location: 19p13.2

Recognizes mouse KLF1. Species sequence homology: human.

Highly Purified
Highly Purified

Supplied as a lyophilized powder in PBS.

May be stored at 4 degree C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Small volumes of KLF1 peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

C-terminus of aa- ATAETALPSISTLT.

Molecular Biology; MB-Peptides

ELISA (EL/EIA)

Suitable for use in ELISA.

38,221 Da[Similar Products]

Kruppel-like factor 1 (erythroid)

Krueppel-like factor 1; monoclonal antibody A3D8; erythroid Kruppel-like factor; erythroid krueppel-like transcription factor; erythroid-specific transcription factor EKLF

Krueppel-like factor 1

EKLF; EKLF  [Similar Products]

KLF1_HUMAN

This gene encodes a hematopoietic-specific transcription factor that induces high-level expression of ***** beta-globin and other erythroid genes. The zinc-finger protein binds to the DNA sequence CCACACCCT found in the beta hemoglobin promoter. Heterozygous loss-of-function mutations in this gene result in the dominant In(Lu) blood phenotype. [provided by RefSeq, Oct 2009]

Function: Transcription regulator of erythrocyte development that probably serves as a general switch factor during erythropoiesis. Is a dual regulator of fetal-to-***** globin switching. Binds to the CACCC box in the beta-globin gene promoter and acts as a preferential activator of this gene. Furthermore, it binds to the BCL11A promoter and activates expression of BCL11A, which in turn represses the HBG1 and HBG2 genes. This dual activity ensures that, in most *****s, fetal hemoglobin levels are low. Able to activate CD44 and AQP1 promoters. When sumoylated, acts as a transcriptional repressor by promoting interaction with CDH2/MI2beta and also represses megakaryocytic differentiation

By similarity. Ref.6 Ref.7 Ref.8

Subunit structure: Interacts with PCAF; the interaction does not acetylate EKLF and inhibits its transactivation activity

By similarity. Interacts with CREBBP/CBP and EP300; the interactions enhance the transactivation activity. Interacts with TFB1. Ref.5 Ref.8

Subcellular location: Nucleus. Note: Colocalizes with SUMO1 in nuclear speckles

By similarity. Ref.6

Tissue specificity: Expression restricted to ***** bone marrow and fetal liver. Not expressed in myeloid nor lymphoid cell lines. Ref.1 Ref.2

Post-translational modification: Acetylated; can be acetylated on both Lys-274 and Lys-288. Acetylation on Lys-274 (by CBP) appears to be the major site affecting EKLF transactivation activity

By similarity.Sumoylated; sumoylation, promoted by PIAS1, leads to repression of megakaryocyte differentiation. Also promotes the interaction with the CDH4 subunit of the NuRD repression complex

By similarity.Phosphorylated primarily on serine residues in the transactivation domain. Phosphorylation on Thr-23 is critical for the transactivation activity

By similarity.

Polymorphism: Genetic variations in KLF1 underlie the fetal hemoglobin quantitative trait locus 6 (HBFQTL6) [

MIM:613566]. Classic hereditary persistence of fetal hemoglobin (HPFH) is characterized by a substantial elevation of fetal hemoglobin (HbF) in ***** red blood cells. There are no other phenotypic or hematologic manifestations. In healthy *****s, fetal hemoglobin (HbF) is present at residual levels (less than 0.06% of total hemoglobin) with over 20-fold variation. Ten to fifteen percent of *****s fall within the upper tail of the distribution.Genetic variations in KLF1 underlie the blood group-Lutheran inhibitor (In(Lu)) phenotype [

MIM:111150]; also known as dominant Lu (a-b-) phenotype. In(Lu) is characterized phenotypically by the apparent absence of the Lu antigen (BCAM) on red blood cells during serologic tests: Lu(a-b-).

Involvement in disease: Congenital dyserythropoietic anemia 4 (CDA4) [MIM:613673]: A blood disorder characterized by ineffective erythropoiesis and hemolysis resulting in anemia. Circulating erythroblasts and erythroblasts in the bone marrow show various morphologic abnormalities. Affected individuals with CDA4 also have increased levels of fetal hemoglobin.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.6

Sequence similarities: Belongs to the krueppel C2H2-type zinc-finger protein family.Contains 3 C2H2-type zinc fingers.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.